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Available online 9 January 2016Cancer stem cells (CSCs) drive tumour spread and therapeutic resistance, and can undergo epithelial-to-
mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) to switch between epithelial
and post-EMT sub-populations. Examining oral squamous cell carcinoma (OSCC), we now show that increased
phenotypic plasticity, the ability to undergo EMT/MET, underlies increased CSC therapeutic resistance within
both the epithelial and post-EMT sub-populations. The post-EMT CSCs that possess plasticity exhibit particularly
enhanced therapeutic resistance and are deﬁned by a CD44highEpCAMlow/−CD24+ cell surface marker proﬁle.
Treatment with TGFβ and retinoic acid (RA) enabled enrichment of this sub-population for therapeutic testing,
through which the endoplasmic reticulum (ER) stressor and autophagy inhibitor Thapsigargin was shown to se-
lectively target these cells. Demonstration of the link between phenotypic plasticity and therapeutic resistance,
and development of an in vitromethod for enrichment of a highly resistant CSC sub-population, provides an op-
portunity for the development of improved chemotherapeutic agents that can eliminate CSCs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Oral squamous cell carcinoma (OSCC) has an annual worldwide in-
cidence of over 300,000 cases, a mortality rate of 48% (Torre et al.,
2015), and commonly develops therapeutic resistance (da Silva et al.,
2012). Resistance to therapeutic regimens is amajor problem for cancer
therapy, as it precludes complete ablation of the tumour and enables
local and distant tumour recurrence, themain cause of cancermortality.
Cancer stem cells (CSCs), the sub-population of tumour cells that pos-
sess tumour-initiating potential (Clarke et al., 2006; Driessens et al.,
2012), express heightened resistance to therapy compared to the ma-
jority non-stem cell population (Gupta et al., 2009; Li et al., 2008) and
also drive tumour invasion and metastasis (Charafe-Jauffret et al.,
2010; Hermann et al., 2007). In common with several other solid tu-
mours, CSCs in OSCC are CD44+ (Prince et al., 2007). However it has re-
cently become apparent that, despite being genetically homogenous,
CSCs exhibit heterogeneous phenotypes (Biddle et al., 2011; Hermann
et al., 2007; Liu et al., 2014). It has further been demonstrated that
CSC heterogeneity within a tumour provides a non-genetic source of
variation in therapeutic response (Kreso et al., 2013), although the
CSC sub-populations underlying this variation have not been
elucidated.d Cutaneous Research, Blizard
. This is an open access article underEpithelial-to-mesenchymal transition (EMT) is a developmental pro-
cess in which epithelial cells acquire a migratory mesenchymal pheno-
type (Hay, 2005), and is often re-activated in cancer to drive tumour
invasion and metastasis (Gjerdrum et al., 2010; Yang et al., 2008). In
OSCC, the secreted cytokine TGFβ is an inducer of EMT and high EMT
activity correlates with poor prognosis (Jensen et al., 2015). Mesenchy-
mal-to-epithelial transition (MET), where migratory tumour cells revert
back to an epithelial phenotype, also occurs in tumours and is often re-
quired in order to enable new tumour growth at metastatic sites (Tsai
et al., 2012). Therefore, a level of phenotypic plasticity that enables se-
quential EMT and MET is important to tumour progression (Brabletz,
2012). This phenotypic plasticity is epigenetically regulated (Chaffer
et al., 2013; Ke et al., 2010), and not all cells within the epithelial and
post-EMT sub-populations possess the plasticity required to enable
EMT/MET (Biddle et al., 2011; Chaffer et al., 2013).
We previously identiﬁed two distinct CSC sub-populations in OSCC:
CD44+EpCAMhigh proliferative epithelial CSCs and CD44highEpCAMlow/−
migratory/metastatic post-EMT CSCs (Biddle et al., 2011). Cells were
able to switch between these two sub-populations by undergoing EMT
and MET. Equivalent CSC sub-populations have now also been identiﬁed
in breast cancer (Liu et al., 2014; Sarrio et al., 2012). We also identiﬁed a
hierarchy of plasticitywithin the post-EMTCSC sub-population, such that
only a subset of post-EMTCSCs could undergoMET to return to an epithe-
lial phenotype (Biddle et al., 2011).
In the present study, we sought to examine the therapeutic resistance
of heterogeneous CSC sub-populations in OSCC. We found that cellularthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tance of CSCs. We identiﬁed a sub-population of post-EMT CSCs that are
highly plastic, resistant to chemotherapeutic drugs including the CSC-
targeted therapy (Gupta et al., 2009) salinomycin, and exhibit a CD44-
highEpCAMlow/−CD24+ cell surface marker proﬁle. Their high plasticity
and consequent re-establishment of heterogeneity posed a challenge
for therapeutic testing, and we therefore developed a co-treatment re-
gime of TGFβwith retinoic acid (RA) for stabilization and enrichment of
this sub-population. Gene expression microarray analysis identiﬁed up-
regulation of processes involved in protein turnover in this sub-
population, and this led us to identify Thapsigargin, a sarco/endoplasmic
reticulum Ca2+ ATPase (SERCA) inhibitor (Ganley et al., 2011), as a com-
pound that selectively targets these cells. Finally, we demonstrated that
fresh OSCC tumour specimens contain CSC sub-populations analogous
to those identiﬁed in cell lines.
2. Materials and Methods
2.1. Cell Culture
Cell culture, including suspension culture for sphere assays,was per-
formed as previously described (Biddle et al., 2011). The CA1 cell line
was previously described (Biddle et al., 2011), and the LM cell line
was recently derived in our laboratory from an OSCC of the mandibular
region of themouth. Cell removal from adherent culturewas performed
using 1× Trypsin–EDTA (Sigma, T3924) at 37 °C. For TGFβ and RA treat-
ment, cells were plated at a density of 10,000 cells perml and TGFβ and
RA were added to cell culture at the indicated concentrations. Medium
and TGFβ and RA were replaced every two days for at least six days
and until enough cells were produced for the required assays,whilst en-
suring continued sub-conﬂuence. Floating cells in culture are greatly
enriched for the post-EMT sub-population; therefore, except for when
treated with TGFβ or RA, the ﬂoating cells were used at each passage
of pEMT-P in order to maintain the post-EMT sub-population.
2.2. Single Cell Cloning
Single cell cloning was performed as previously described (Biddle
et al., 2011), using limiting dilution and microscopic examination of
wells to identify those that contain a single cell. Clonal sub-lines were
maintained under standard tissue culture conditions.
2.3. Flow Cytometry and FACS
Flow cytometry was performed as previously described (Biddle
et al., 2011). Antibodies for cell line staining were CD44-PE (clone
G44-26, BD Bioscience), CD24-FITC (clone ML5, BD Bioscience) and
EpCAM-APC (clone HEA-125, Miltenyi Biotec). For fresh tumour cells,
β4-integrin-PE (Epi-P39-9B, BD Bioscience) was added and CD44-PE
was replaced with CD44-PerCP/Cy5.5 (clone G44-26, BD Bioscience).
Single stained controls were performed for compensation, and isotype
controls were performed to set negative gating.
2.4. Immunoﬂuorescence
FACS sorted tumour cell sub-populationswere smeared onto Poly-L-
Lysine slides (Thermo Scientiﬁc) and incubated at 37 °C for 30 min to
promote attachment. Cells were ﬁxed in 4% paraformaldehyde,
permeabilised with 0.25% Triton-X (Sigma) in phosphate buffered sa-
line (PBS) (Sigma, D8662), and then blocked overnight in 1% bovine
serum albumin (BSA) in PBS. Cells were then incubated overnight
with primary antibodies in PBS/1% BSA, washed twice in PBS/1% BSA,
and then incubated for 1 h with secondary antibodies in PBS/1% BSA.
Cells were washed twice in PBS/1% BSA, incubated for 1 min with
DAPI (Sigma) at 1 μg/ml in PBS, washed once in PBS and then mounted
with Immu-Mount (Thermo Scientiﬁc). Imaging was performed at200× magniﬁcation, and exposure time was the same for all samples.
Images were processed in Adobe Photoshop, with the threshold for
high versus low staining the same for all samples. Antibody details can
be found in the supplementary information.
2.5. RNA Extraction, cDNA Synthesis and QPCR
RNA extraction, cDNA synthesis and QPCRwere performed as previ-
ously described (Biddle et al., 2011). Primer sequences are listed in the
supplementary information.
2.6. Drug Dose Response Assays
Cells were plated at 1000 cells per well in ﬂat-bottomed 96-well tis-
sue culture plates (Corning). 24 h later, drugs were added at 4 different
concentrations in triplicate technical replicates, with triplicate untreat-
ed control wells. 72 h after drug addition, cells were ﬁxed in 4% parafor-
maldehyde and washed in PBS. For automated microscope analysis,
cells were permeabilised with 0.1% Triton-X (Sigma) in PBS, then
stained with CellMask deep red (Life Technologies H32721, used at
1:30,000 dilution) and 1 μg/ml DAPI (Sigma) for 1 h. Cells were washed
twice with PBS. Cell images were acquired using an InCell 1000 auto-
matedmicroscope (GE), and then analysed using InCell Developer Tool-
box software (GE) to determine the number of cells. Data was averaged
for the triplicate technical replicates and normalized to the untreated
wells. Results from at least three independent biological repeat experi-
ments were entered into Graph-Pad Prism software to determine the
dose response curve, IC50 and 95% conﬁdence intervals for the IC50,
using the nonlinear regression analysis of log(inhibitor) versus response
with a variable slope. Drug details can be found in the supplementary
information.
2.7. Microarray Analysis
RNAwas extractedusing theRNeasymicrokit (Qiagen) and analysed
using an Illumina Human HT-12 v4 gene expression array. The results
were analysed using the GenomeStudio software (Illumina), with
quantile normalization and a false discovery rate ﬁlter of 5% in differen-
tial expression analysis. The top 150 differentially expressed genes from
each analysis were analysed with the functional annotation clustering
tool on the DAVID database (Huang da et al., 2009a, 2009b). Microarray
data are deposited in the GEO database under the accession numbers
GSE74578 and GSE74580.
2.8. Transplantation Into Immunodeﬁcient Mice
NOD/SCIDmicewere obtained from Jackson Laboratories. Mice used
in this study were of mixed gender and older than 6 weeks of age. The
mice were maintained in a certiﬁed isolation facility under a pathogen
free environment with standard 12/12 h day and night cycle, in accor-
dance with European guidelines. All animal procedures were approved
by the Norwegian Animal Research Authority. Cells were harvested
from adherent culture and resuspended in 50 μl of Matrigel (BD Biosci-
ences) on ice. The suspension was injected orthotopically into the
tongues of NOD/SCID mice. Tumours were detected by palpation and
the tumour volume was manually assessed with a digital calliper.
2.9. Isolation of Cells From Human Tumours
Tumour specimens were obtained from the pathology department
at Barts Health NHS Trust, with full local ethical approval and patients'
informed consent. Specimen site was selected to avoid both the tumour
margin and necrotic core, and specimens were kept overnight at 4 °C in
epithelial growth medium (termed FAD) with 10% FBS (Locke et al.,
2005). Specimenswerewashed in PBS to remove blood,minced into ap-
proximately 1 mm3 pieces using scalpels, and then incubated with
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(Sigma, C0130) in DMEM. An equal volume of DMEM containing 10%
FBS was then added and the mixture was ﬁltered through a 70 μm cell
strainer prior to antibody staining for FACS.
2.10. Reagents
TGFβ (Millipore, GF111) was prepared as a 2 μg/ml stock solution in
4 mM HCl with 1 mg/ml BSA. Final concentrations were as indicated in
the text. RA (Sigma, R2625) was prepared as a 10 mM stock solution in
dimethyl sulfoxide (DMSO). Final concentrationwas 5 μM, a dose deter-
mined to be the highest dose that avoids toxicity.
2.11. Statistical Analysis
The number of biological repeats (n) for each experimentwas at least
three, except for themethod development data in Fig. S2B–S2E and this is
stated in the ﬁgure legend. Data is presented as mean ± s.e.m. Statistical
analysis was performed using a two-sided t-test, and signiﬁcance is indi-
cated in the ﬁgures as * for P b 0.05 and ** for P b 0.01.
3. Results
3.1. CSC Plasticity IntersectsWith EMT to Determine Therapeutic Resistance
We initially examined the therapeutic resistance of post-EMT CSCs.
We examined survival of CD44highEpCAMlow/− post-EMT CSCs in the
CA1 and LM OSCC cell lines using two chemotherapeutic agents, pacli-
taxel and cisplatin (Fig. 1A). The post-EMT CSCs preferentially survived
paclitaxel treatment, but showed no preferential survival of cisplatin
treatment. This indicates that cisplatin resistance is not driven by EMT,
and raises the question ofwhether resistance to cisplatin depends on al-
ternative CSC sub-populations.
To investigatewhether CSC plasticity could inﬂuence therapeutic re-
sponse, we generated four clonal CA1 sub-lines which differ in their
phenotypic plasticity: (1) a phenotypically stable epithelial sub-line
with limited ability to undergo EMT (Epi-S); (2) a plastic epithelial
sub-line with enhanced ability to undergo EMT (Epi-P); (3) a stable
post-EMT sub-line unable to undergo MET (pEMT-S) (Biddle et al.,
2011); and (4) a plastic post-EMT sub-line that can undergo MET
(pEMT-P) (Biddle et al., 2011) (Fig. S1A and S1B). Despite maintenance
of plasticity during initial derivation and early expansion, extended pas-
sage of both Epi-P and pEMT-P resulted in reduced plasticity and mor-
phological changes (Fig. S1C and S1D), indicating a shift to a more Epi-
S and pEMT-S-like state, respectively.
We investigated whether differences in plasticity could inﬂuence
therapeutic response by assessing the responses of the four clonal sub-
lines to the chemotherapeutic drugs paclitaxel and cisplatin (Figs. 1B
and C and S1E). Salinomycin, an antibiotic previously reported to target
post-EMT CSCs (Gupta et al., 2009), was also tested. Post-EMT sub-lines
were resistant to paclitaxel, irrespective of plasticity, whereas epithelial
sub-lines were sensitive. Contrastingly, plastic sub-lines (both Epi-P and
pEMT-P)were resistant to both cisplatin and salinomycin, whereas stable
sub-lines (both Epi-S and pEMT-S) were sensitive. pEMT-P, being both
post-EMT and plastic, exhibited resistance to all three drugs. Extended
passage resulted in loss of cisplatin and salinomycin resistance in both
the Epi-P and pEMT-P sub-lines, whereas paclitaxel resistance was main-
tained over extended passage in the pEMT-P sub-line. This indicated that,
whilst resistance to paclitaxel was determined by possession of a post-
EMT identity, resistance to cisplatin and salinomycin was determined by
possession of phenotypic plasticity and was lost as the clonal sub-lines
lost their enhanced plasticity over extended passage.
We next sought to identify a cell surfacemarker that could be used to
detect plastic CSCs in ﬂow cytometry. CD24was identiﬁed as a potential
marker of plasticity from gene expression microarray analysis compar-
ing Epi-P to Epi-S and pEMT-P to pEMT-S. The percentage of CD24+cells was higher in ﬂow cytometric analysis of Epi-P and pEMT-P com-
pared to Epi-S and pEMT-S, respectively, and was reduced over extend-
ed passage (Fig. S1F and S1G) in concert with loss of plasticity and drug
resistance. The CD24+ fraction from pEMT-P was enriched in the ability
to undergo MET, relative to the CD24− pEMT-P fraction (Fig. 1D),
conﬁrming CD24 as a marker of plasticity. To determine the
contribution of the CD44highEpCAMlow/−CD24+ plastic post-EMT CSCs
to therapeutic resistance, we examined their survival within the post-
EMT sub-population in the CA1 and LM OSCC cell lines upon treatment
with paclitaxel or cisplatin (Fig. 1E). The CD24+ plastic post-EMT CSCs
preferentially survived cisplatin treatment, but showed no preferential
survival of paclitaxel treatment compared to the rest of the post-EMT
sub-population. This was in agreementwith the ﬁndings above showing
that post-EMT CSC sub-populations are resistant to paclitaxel irrespec-
tive of plasticity, whereas plasticity is important for resistance to cisplat-
in (Fig. 1F).
To determine if the four clonal sub-lines had different in vivo tumour
initiating properties, we performed orthotopic xenograft studies in
NOD/SCID mice. Injecting 5000 cells from Epi-S, Epi-P or pEMT-P pro-
duced tumours in 6/6, 5/6 and 5/6 mice respectively, whereas only 1
mouse out of 6 formed a tumour when injected with pEMT-S
(Fig. S1H). Epi-S and the parental CA1 line both produced fast-
growing tumours, Epi-P and pEMT-P produced slower-growing tu-
mours, and the single tumour produced by pEMT-S only grew to a
very small size (Fig. S1I). Importantly, pEMT-S produced the greatest
number of tumourspheres in suspension culture (Fig. S1J), an assay of
self-renewal that biases towards self-renewing post-EMT cells (Biddle
et al., 2011; Chaffer et al., 2006). This supports the notion that the
pEMT-S sub-population is not deﬁcient in the ability to self-renew.
Quantitative PCR with reverse transcription (QPCR) (Fig. S1K) showed
that, compared to the parental CA1 line, pEMT-S and pEMT-P had up-
regulated expression of the EMTmarkers Vimentin and Zeb1 and down-
regulated expression of the epithelial markers E-cadherin and Keratin
15. The transcription factor Prrx1, which prevents MET (Ocana et al.,
2012), was highly expressed in pEMT-S. Expression of Calgranulin B, a
marker of epithelial terminal differentiation (Martinsson et al., 2005),
was low in all four clonal sub-lines. These data demonstrate that both
drug sensitive and drug resistant sub-populations contain self-
renewing CSCs. There is evidence that post-EMT CSCs must undergo
MET in order to drive new tumour formation (Ocana et al., 2012; Tsai
et al., 2012), and our data suggest that the lack of plasticity of the
pEMT-S sub-line underlies its inability to initiate tumour formation.
3.2. Co-treatment With TGFβ and RA Maintains Plasticity and Therapeutic
Resistance
We next sought to block the loss of plasticity that occurs over extend-
ed passage in pEMT-P, in order to determine whether this would also
block the loss of cisplatin resistance. A method for experimental mainte-
nance of cells in the plastic post-EMT sub-population would also be ad-
vantageous for therapeutic testing, as this sub-population exhibits
resistance to all drugs tested so far. TGFβ induces EMT (Biddle et al.,
2011), but extended TGFβ treatment drove the CA1 post-EMT sub-
population into a stable post-EMT state (Fig. S2A). By contrast, RA induces
epithelial differentiation (Metallo et al., 2008) and opposes TGFβ activity
during development (Chen et al., 2007). We therefore tested whether RA
could block the transition of pEMT-P into a pEMT-S-like state and act in
concert with TGFβ to restrain cells in the plastic post-EMT sub-
population. 5 μM RA caused increased MET of pEMT-P, creating a mixed
population of epithelial and post-EMT cells, and had no effect on pEMT-
S. The effect of RA was abrogated by 5 ng/ml TGFβ and did not prevent
5 ng/ml TGFβ from driving cells into a stable post-EMT state (Fig. S2B
and S2C). However, by titrating the TGFβ dose we were able to establish
a co-treatment regime that enabled maintenance of the plastic post-EMT
sub-population (0.5 ng/ml TGFβ in combination with 5 μMRA) (Fig. S2D
and S2E). Importantly, treatment of pEMT-P with 0.5 ng/ml TGFβ and
Fig. 1.CSC plasticity intersectswith EMT to determine therapeutic resistance. A, Flowcytometric analysis of the surviving cells after 3 days treatment of the CA1 and LM cell lineswith 5 nM
paclitaxel or 3 μM cisplatin followed by a 5 day recovery period. The size of the post-EMT sub-population (CD44highEpCAMlow/−) as % of total cells (**P b 0.01). B, Dose response of each
clonal sub-line and the parental CA1 cell line to cisplatin, paclitaxel and salinomycin. Cell viability expressed as number of cells remaining as a percentage of those in the control wells.
Signiﬁcance (**P b 0.01) was determined by comparison of Epi-P and pEMT-P to the parental CA1 line for cisplatin and salinomycin, and by comparison of pEMT-P to the parental CA1
line for paclitaxel. C, Summary of the results of the dose response assays, showing the sub-lines that exhibit resistance to each drug. D, The size of the epithelial sub-population (as % of
total cells) in ﬂow cytometric analysis 7 days after plating equal numbers of FACS sorted CD24+ and CD24− cells from pEMT-P (**P b 0.01). E, Flow cytometric analysis of the
surviving cells after 3 days treatment of the CA1 and LM cell lines with 5 nM paclitaxel or 3 μM cisplatin followed by a 5 day recovery period. Percentage of the post-EMT sub-
population (CD44highEPCAMlow/−) that is CD24+ (*P b 0.05, **P b 0.01). F, Scheme summarising the convergence of therapeutic resistance on a plastic post-EMT CSC sub-population,
and indicating cell surface marker proﬁles for the four different CSC sub-populations (in colour). For the panels in this ﬁgure, n ≥ 3 biological repeats and error bars represent mean ±
s.e.m. See also Fig. S1.
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(Figs. 2A and B and S2F and S2H). pEMT-P retained the ability to undergo
MET upon treatment withdrawal (Fig. 2C), indicating maintenance of
plasticity. Resistance to cisplatin and paclitaxel was maintained in
pEMT-P treated with TGFβ and RA (Figs. 2D and S2I), demonstrating
that maintained CSC plasticity results in maintenance of drug resistance.
To validate this protocol, we tested it using a second cell line. We
FACS sorted the CD44highEpCAMlow/−CD24+ fraction from the LM
OSCC cell line and treated the cells with TGFβ and RA during population
expansion in culture. Treatment with TGFβ and RAmaintained the cells
in a CD44highEpCAMlow/−CD24+ state (Figs. 2E and F and S2G and S2H).
The ability to undergo MET upon treatment withdrawal was alsomaintained (Fig. 2G), as was resistance to cisplatin and paclitaxel
(Figs. 2H and S2J). Therefore, plasticity canbemaintained in FACS sorted
CD44highEpCAMlow/−CD24+ cells and this results in maintenance of
drug resistance. In summary, we have developed a TGFβ+RA protocol
for the enrichment of the plastic post-EMT CSC sub-population which
dispenses with the need for single cell cloning experiments.
3.3. Thapsigargin Speciﬁcally Targets the Drug Resistant Plastic Post-EMT
CSCs
To identify targetable cellular processes for therapeutic testing, we
performed functional annotation clustering analysis of gene expression
Fig. 2.Maintaining plasticity also maintains therapeutic resistance. A and B, Flow cytometric analysis of pEMT-P untreated (control) or treated with TGFβ, RA, or TGFβ+ RA, and the
parental CA1 line. Size of the post-EMT sub-population (CD44highEpCAMlow/−) (A), and size of the plastic post-EMT sub-population (CD44highEPCAMlow/−CD24+) (B), as % of total
cells. C, Size of the epithelial sub-population (as % of total cells) 7 days after withdrawal of the different treatments from pEMT-P. D, Dose response to cisplatin and paclitaxel of pEMT-
P after treatment with TGFβ and RA. Cell viability expressed as number of cells remaining as a percentage of those in the control wells. E and F, Flow cytometric analysis of the
CD44highEpCAMlow/−CD24+ fraction (CD24+ fraction) from the LM line, untreated (control) or treated with TGFβ, RA, or TGFβ+ RA, and the parental LM line. Size of the post-EMT
sub-population (CD44highEpCAMlow/−) (E), and size of the plastic post-EMT sub-population (CD44highEPCAMlow/−CD24+) (F), as % of total cells. G, Size of the epithelial sub-population
(as % of total cells) 7 days after withdrawal of the different treatments from the LM CD44highEpCAMlow/−CD24+ fraction. H, Dose response to cisplatin and paclitaxel of the LM
CD44highEpCAMlow/−CD24+ fraction after treatment with TGFβ and RA. Cell viability expressed as number of cells remaining as a percentage of those in the control wells. For the
panels in this ﬁgure, n ≥ 3 biological repeats and error bars represent mean ± s.e.m. Signiﬁcance (**P b 0.01) was determined by individual comparisons of TGFβ+ RA treatment to
each of the other treatments, except for the paclitaxel dose response curves where comparison was to the parental line only. See also Fig. S2.
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pEMT-P compared to Epi-S and pEMT-S) and for genes upregulated in
the TGFβ+ RA protocol for retention of plasticity (TGFβ+ RA treatedpEMT-P and CD44highEpCAMlow/−CD24+ LM fraction compared to con-
trol and TGFβ treatments alone) (Tables S1–S3). Multiple cellular pro-
cesses were upregulated in all three analyses, predominantly
Fig. 3. Thapsigargin speciﬁcally targets the drug resistant plastic post-EMT CSCs. A and B, Dose response to baﬁlomycin a1, tunicamycin and thapsigargin of pEMT-P (A) and the
CD44highEpCAMlow/−CD24+ fraction (CD24+ fraction) from the LM line (B) after no treatment (control) or treatment with TGFβ or TGFβ+ RA, and the corresponding parental line.
Untreated pEMT-S was also included in A. Cell viability expressed as number of cells remaining as a percentage of those in the control wells. For the panels in this ﬁgure, n ≥ 3
biological repeats and error bars represent mean ± s.e.m. Signiﬁcance (**P b 0.01) was determined by comparison of TGFβ+ RA treatment to the corresponding parental line. See also
Fig. S3.
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cluding lysosomes and other membrane-bound organelles) and protein
complex biogenesis, indicating high protein turnover. These processes
may be required for the cellular remodelling intrinsic to phenotypic
plasticity, and we attempted to sensitize the plastic post-EMT sub-
population to cell death by targeting processes involved in protein turn-
over in TGFβ+RA treated pEMT-P and CD44highEpCAMlow/−CD24+ LM
fraction. CX-5461, a selective inhibitor of RNApol1 (Drygin et al., 2011),
did not cause increaseddeath of theplastic post-EMT sub-population ei-
ther alone or in combination with cisplatin (Fig. S3A–S3C). Baﬁlomycin
A1, an inhibitor of lysosomal fusion (Yamamoto et al., 1998), and
Tunicamycin, an inhibitor of protein folding in the endoplasmic reticu-
lum (ER) that induces the ER unfolded protein response (UPR) (Xu
et al., 2005), both induced increased death of post-EMT cells compared
to the CA1 and LMparental lines (Figs. 3A andB and S3Dand S3E). How-
ever, they did not speciﬁcally target the plastic post-EMT sub-
population and targeting of post-EMT cells was weak. Thapsigargin, a
SERCA inhibitor that both induces the ERUPR and inhibits lysosomal fu-
sion (Ganley et al., 2011), speciﬁcally targeted the plastic post-EMT sub-
population in both the CA1 and LM lines (Figs. 3A and B and S3D and
S3E). Therefore, the TGFβ+ RA protocol can be used to identify com-
pounds that target the plastic post-EMT CSC sub-population, and we
have identiﬁed Thapsigargin as one such compound.3.4. OSCC Tumour Specimens Contain CSC Sub-populations With
Corresponding Properties to Those Identiﬁed in Cell Lines
We next investigated whether CSC sub-populations analogous to
those identiﬁed in cell lines exist in fresh clinical specimens of OSCC.
The distribution of CD44, EpCAM and CD24 staining on the specimen
FACS plots corresponded with that seen in cell lines (Figs. 4A and B and
S4A). Cells freshly isolated from OSCC tumours survive poorly ex vivo,
sowe assessed their attributes by direct antibody staining of FACS sorted
post-EMT CD44highEpCAMlow/−CD24+ and CD44highEpCAMlow/−CD24−
fractions and epithelial CD44+EpCAMhighCD24+ and CD44+
EpCAMhighCD24− fractions from 7 specimens (Figs. 4C and S4B–
S4H). Both the post-EMT CD44highEpCAMlow/− fractions stained
highly for vimentin and low for pan-keratin, whereas both the epi-
thelial CD44+EpCAMhigh fractions stained low for vimentin and
highly for pan-keratin. This conﬁrmed their post-EMT and epithelial
identities, respectively. Activated caspase-3, a marker of cells enter-
ing apoptosis, was used to assess sensitivity to cell death. It was
most highly expressed in the epithelial CD24− fraction, had lowest
expression in the post-EMT CD24+ fraction, and was expressed at
an intermediate level in the epithelial CD24+ and post-EMT
CD24− fractions. This was in agreement with the therapeutic sensi-
tivities of the corresponding cell line sub-populations. Lysosomal
Fig. 4. CSC sub-populationswith the same properties as those identiﬁed in vitro also exist in fresh tumour specimens. A and B, Representative ﬂow cytometric analysis of an OSCC tumour.
CD44 and EpCAM distribution (y-axis; CD44, x-axis; EpCAM, crosshairs set with isotype control) (A), and CD44 and CD24 distribution (y-axis; CD44, x-axis; CD24, crosshairs set with
isotype control) (B). Tumour cells were isolated from stromal cells using β4-integrin. C, Immunoﬂuorescent antibody staining of FACS sorted cells prepared on slides. Percentage of
cells from the four FACS sorted sub-populations that stain highly for pan-keratin, vimentin, active caspase-3 and LAMP-2. n = 7 tumours and error bars represent mean ± s.e.m.
Signiﬁcance (*P b 0.05, **P b 0.01) was determined by comparison of the epithelial fractions to the post-EMT fractions for pan-keratin and vimentin, and by comparisons indicated by
horizontal lines for active caspase-3 and LAMP-2. See also Fig. S4.
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we stained tumour fractions for the lysosome marker LAMP-2.
LAMP-2 was more highly expressed in the post-EMT CD24+ and ep-
ithelial CD24+ fractions than in either CD24− fraction, again in
agreement with the cell line data. These data indicate that CSC
sub-populations exist in fresh tumour specimens with correspond-
ing properties to those identiﬁed in cell lines.
4. Discussion
There has recently been considerable focus on the role of CSCs in tu-
mour therapeutic resistance (Gupta et al., 2009; Li et al., 2008) but, de-
spite the existence of heterogeneous CSC phenotypes (Biddle et al.,
2011; Hermann et al., 2007; Liu et al., 2014), differences in therapeutic
resistance between CSC sub-populations have not previously been in-
vestigated.We ﬁnd that differing phenotypic plasticity is a key determi-
nant of differences in therapeutic resistance between CSC sub-
populations. Given the importance of phenotypic plasticity in tumour
invasion and metastasis (Brabletz, 2012; Tsai et al., 2012), a sub-
population of CSCs that exhibit both phenotypic plasticity and thera-
peutic resistance presents a potent threat and is likely to be an impor-
tant target for therapeutic intervention. Our development of a method
for enrichment of this most resistant CSC sub-population through co-
treatment with TGFβ and RA provides a means for producing large
numbers of these cells for drug development studies. This sub-
population possesses a CD44highEpCAMlow/−CD24+ cell surface marker
proﬁle, and can therefore bemonitored byﬂow cytometric analysis. As a
proof of principle, we performed a targeted study and identiﬁed the
SERCA inhibitor Thapsigargin as a compound to which this sub-
population is selectively sensitive, demonstrating the potential of this
method for therapeutic development. Identiﬁcation of corresponding
CSC sub-populations with corresponding resistance to cell death in
fresh clinical specimens of OSCC indicates that this is an important
new aspect of cancer biology with relevance to human tumours.
The precise mechanism linking plasticity with drug resistance re-
mains to be determined. In this study, we identiﬁed the importance to
plastic CSCs of processes involved in protein turnover. This suggests
that rapid turnover of cellular contents might be required for cellular re-
modelling during transitions between phenotypic states, for which plas-
tic CSCs are prepared. This rapid turnover is likely to exert considerable
cellular stress, and the observed therapeutic resistance might be a by-
product of mechanisms intended to protect the cell from stress during
phenotypic transitions (Buchberger et al., 2010; Kroemer et al., 2010).
We observed that plastic CSCs are extremely sensitive to Thapsigargin,
which targets both lysosomal degradation and ER protein processing
(Ganley et al., 2011). Interfering with ER protein processing would beexpected to cause accumulation ofmisfolded proteins, and simultaneous
inhibition of lysosomal degradation might prevent degradation of
misfolded proteins so that they accumulate and overwhelm the cell.
Plastic CSCs, undergoing rapid protein turnover, might be particularly
sensitive to these perturbations.
In this study, CD24 was identiﬁed as a marker of plastic CSC sub-
populations. CD24 is a mucin-like adhesion molecule expressed
on the cell surface of multiple different cell types through a
glycosylphosphatidylinositolmembrane anchor, and high CD24 expres-
sion has been associated with more aggressive disease in ovarian,
breast, lung and prostate cancer (Kristiansen et al., 2004). CD24 is a li-
gand for endothelial cell P-selectin, suggesting that it may act in meta-
static dissemination of tumour cells (Aigner et al., 1997), and it has
been shown to promote both tumour cell invasion (Bretz et al., 2012)
and metastasis (Lau et al., 2014). CD24 was initially identiﬁed as a neg-
ative marker for CSCs in breast cancer (Al-Hajj et al., 2003), but has
more recently been described as a positive CSC marker in lung cancer
(Lau et al., 2014), colorectal cancer (Yeung et al., 2010), and triple-
negative breast cancer (Azzam et al., 2013). It has been shown to
mark a transient chemoresistant cell state in lung cancer (Sharma
et al., 2010) and breast cancer (Goldman et al., 2015). Furthermore,
CD24 has been implicated in regulation of EMT (Lim et al., 2014). Fur-
ther studies into a potential role for CD24 in the control of CSC thera-
peutic resistance and plasticity may elucidate downstream regulatory
mechanisms and suggest new therapeutic targets.
The analysis of fresh clinical specimens in this study provides a
ﬁrst indication that our in vitro model accurately models sub-
populations existing in human tumours. However, to fully realise
the potential of our in vitro model system for therapeutic develop-
ment, future studies should further investigate its relevance to the
in vivo disease state. Other tumour models, utilising fresh human tu-
mour specimens, will need to be utilised to conﬁrm the therapeutic
responses of CSC sub-populations. It will also be important to inves-
tigate both a) the power of markers of plastic CSC sub-populations
for predicting patient therapeutic response and b) the effect of clin-
ical interventions in human subjects on markers of plastic CSC sub-
populations.
This study has demonstrated that phenotypic plasticity underlies
CSC therapeutic resistance. The demonstration that a highly plastic
and drug resistant CSC sub-population can be stabilized by balancing
opposing signalling pathways, and thus enriched in vitro, provides an
opportunity for the development of novel therapeutic strategies
targeting drug resistant CSCs thatmay otherwise survive therapeutic in-
tervention and drive tumour recurrence. Given the similar underlying
biology of epithelial tumours, theseﬁndings are likely to also be relevant
to other cancers.
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